TCDB: Medical Relevance in Disease & Drug Discovery

The Transporter Classification Database, known as TCDB, is a curated reference system that catalogs membrane transport proteins across all forms of life, and its medical relevance has grown sharply as researchers recognize that these proteins sit at the center of drug absorption, disease mechanisms, and treatment resistance. Maintained as the only transporter classification system approved by the International Union of Biochemistry and Molecular Biology, TCDB now holds information on over 20,000 proteins organized into more than 1,500 families.¹ That scope matters because membrane transporters are involved in everything from how your body handles a pill you swallow to why certain cancers shrug off chemotherapy. Understanding what TCDB catalogues, and how researchers use it, opens a window into some of the most active frontiers in drug discovery.

What TCDB Actually Contains

TCDB is a freely available online resource that classifies transport systems from evolutionary, structural, and functional perspectives. Each entry includes sequence data, functional annotations, and, where available, links to high-resolution three-dimensional structures. As of its 2021 update, the database contained over 15,500 non-redundant transport systems with structural data for roughly 1,567 of them, backed by more than 18,000 reference citations.¹ The classification hierarchy allows researchers to search by sequence similarity, by a transporter’s TC number (its formal address in the system), or by full-text queries, making it straightforward to identify which transporter family a newly discovered protein belongs to.²

The database also bundles bioinformatic tools designed specifically for transport protein research. These include programs for phylogenetic analysis, genome-wide transporter annotation, and functional prediction. A separate automated annotation pipeline, TransAAP, uses TCDB alongside curated Pfam and TIGRFAM data to predict and annotate all the membrane transport proteins in a given organism’s genome from raw sequence data alone.³ For clinical researchers, this means TCDB is not just a lookup table; it is an active research platform that can flag which transporters a pathogen carries, which families those transporters belong to, and what functional role they are likely to play.

Why Membrane Transporters Matter for Medicine

Every cell is enclosed by a lipid membrane, and almost nothing gets in or out without help from specialized proteins. Those proteins, the transporters, govern which nutrients enter, which waste products leave, and which drugs reach their intended targets. Membrane transporters are major determinants of how a drug is absorbed, distributed through the body, and eventually cleared.⁴ When these proteins malfunction due to genetic mutations, diseases follow. When they work too well, they can pump drugs right back out of cells before those drugs do any good.

Despite their central role, transporters remain surprisingly underdeveloped as drug targets. Of the estimated 500 distinct epithelial plasma membrane transporters in humans, fewer than a dozen are targeted by approved drugs, and most of those drugs have been in clinical use for decades.⁵ That gap between biological importance and therapeutic exploitation is one reason TCDB’s catalog has become so valuable: it maps the territory that drug developers are just beginning to explore.

Genetic Diseases Traced to Broken Transporters

Mutations in transporter genes are behind a surprising number of inherited disorders. In the solute carrier (SLC) superfamily alone, defects cause conditions ranging from glucose-galactose malabsorption and familial renal glycosuria to thyroid hormone synthesis defects and certain motor neuron diseases.⁶ Large-scale genetic analyses of SLC genes have revealed that the carrier frequencies of loss-of-function variants mirror well-known population-specific disease patterns, such as cystinuria being more common among Jewish populations, type II citrullinemia in East Asians, and lysinuric protein intolerance in Finns.⁷ These findings give clinical geneticists a practical resource for predicting which transporter diseases are likeliest in a given patient population.

The ABC transporter family tells a similar story. Humans carry about 50 ABC transporters, and by one count, at least 14 of them are linked to 13 distinct genetic diseases. The list includes some well-known conditions: cystic fibrosis (caused by defects in the chloride channel CFTR, classified as an ABC transporter), Stargardt disease and age-related macular degeneration (linked to the retinal transporter ABCA4), adrenoleukodystrophy, Tangier disease, and progressive familial intrahepatic cholestasis.⁸ The retinal transporter ABCA4 alone is associated with a spectrum of inherited macular degenerations beyond Stargardt disease, including cone-rod dystrophy and fundus flavimaculatus.⁹ TCDB’s classification of these transporters into families and superfamilies helps researchers recognize when a new disease gene might be functionally related to a known one, accelerating the process of diagnosis and mechanistic understanding.

ABC Transporters and Cancer Drug Resistance

One of the most frustrating problems in oncology is multidrug resistance, where a tumor that initially responded to chemotherapy stops responding to not just one drug but a whole panel of structurally unrelated drugs. The primary mechanism behind this is the overexpression of ABC transporters on cancer cell surfaces. These pumps actively expel chemotherapy drugs from the cell interior, keeping intracellular drug concentrations too low to kill the tumor.¹⁰ The major culprits include P-glycoprotein (also called ABCB1), breast cancer resistance protein (ABCG2), and the multidrug resistance-associated proteins in the ABCC subfamily.¹¹

Decades of work on inhibiting these pumps directly has produced mixed clinical results; blocking the pump in tumor cells often means blocking the same pump in healthy tissues like the liver and intestine, causing toxicity. Newer strategies aim to be more selective, and TCDB’s detailed classification of the ABC superfamily is part of the foundation for these efforts. By cataloging the structural and functional differences between ABC family members, the database helps researchers identify druggable differences between the transporter variants expressed in tumors and those expressed in normal tissues. Recent reviews highlight a growing range of therapeutic approaches that try to overcome or circumvent ABC-transporter-mediated resistance rather than simply inhibiting the pump head-on.¹²

Neurotransmitter Transporters as Existing Drug Targets

Some of the most prescribed drugs in the world already work by targeting transporters, even if patients do not think of them that way. Selective serotonin reuptake inhibitors (SSRIs) for depression, stimulant medications for ADHD, and several anti-anxiety drugs all act on monoamine transporters: the serotonin transporter (SERT), the norepinephrine transporter (NET), and the dopamine transporter (DAT). These three proteins terminate neurotransmitter signaling by sweeping serotonin, norepinephrine, or dopamine out of the synapse and back into the sending neuron.¹³ Blocking that reuptake raises neurotransmitter levels in the synapse, which is the therapeutic effect. SERT, NET, and DAT are also targets of drugs used for schizophrenia and psychostimulant abuse, and they are major targets for antidepressant drug design broadly.¹⁴

These transporters belong to the SLC6 family within the TCDB classification, and understanding their evolutionary relationships to other SLC6 members has helped researchers look for additional family members that might serve as targets for future neuropsychiatric drugs. The classification framework makes it possible to ask systematic questions: which SLC6 transporters are expressed in the brain but not yet targeted by any drug, and what are they transporting?

SGLT2 Inhibitors and the Cardiometabolic Revolution

Perhaps the best recent example of transporter biology translating into a blockbuster drug class is the story of SGLT2 inhibitors. SGLT2 (sodium-glucose linked transporter type 2) is a protein in the kidney’s proximal tubule that reclaims glucose from urine before it is excreted. Drugs like empagliflozin, canagliflozin, and dapagliflozin block this transporter, causing glucose and sodium to be excreted in the urine. They were originally developed to lower blood sugar in type 2 diabetes, but clinical trials revealed cardiovascular and kidney benefits that nobody fully anticipated.¹⁵

Large outcome trials showed that empagliflozin and canagliflozin reduced a composite of heart attack, stroke, and cardiovascular death, with empagliflozin additionally lowering both cardiovascular mortality and total mortality.¹⁵ Beyond blood sugar, these drugs reduce blood pressure, slow the loss of kidney filtration capacity, and protect against heart failure in patients with or without diabetes.¹⁶ The mechanisms are multifaceted: SGLT2 inhibitors lower pressure inside the kidney’s filtering units, reduce fluid overload, and appear to inhibit the sodium-proton exchanger as well, which may contribute to their cardiac benefits.¹⁷ The SGLT2 story is a textbook case of what can happen when a well-characterized transporter becomes a drug target, and it has energized efforts to look at other renal and intestinal transporters as therapeutic opportunities.

The Blood-Brain Barrier Problem

The brain’s blood vessels are lined with endothelial cells knitted together by tight junctions that form the blood-brain barrier (BBB). This barrier protects the brain from circulating toxins and pathogens but also blocks most drug molecules from entering, which is a major obstacle for treating neurological diseases like Alzheimer’s, Parkinson’s, and brain cancers.¹⁸ The barrier has both a physical component (those tight junctions) and a biochemical component (transporters and enzymes that actively reject or degrade foreign molecules).¹⁹

Some drugs do enter the brain by passive diffusion, but only if they have the right size and chemical properties. For the rest, the only realistic path in is through uptake transporters expressed on the BBB endothelium. TCDB’s catalog of these transporters tells researchers which uptake systems exist, which families they belong to, and what substrates they naturally carry. One particularly promising target is LAT1 (L-type amino acid transporter 1), which is highly expressed at the BBB. Prodrug strategies have been designed so that a drug molecule is chemically disguised to look like an amino acid, tricking LAT1 into carrying it across the barrier.²⁰ Because LAT1 is also overexpressed in many cancers, the same strategy can be used to target drug delivery to tumors, making it a two-for-one opportunity.

Drug-Drug Interactions Mediated by Transporters

When you take two drugs at the same time, one can alter how the other is absorbed or cleared by competing for the same transporter. These transporter-mediated drug-drug interactions are a growing area of regulatory concern. The FDA, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency all now have guidelines requiring drug developers to evaluate whether a new compound inhibits or is transported by key uptake and efflux proteins during preclinical testing.²¹ The transporters flagged in these guidelines, including P-glycoprotein, BCRP, several organic anion and cation transporters, and the MATE efflux proteins, are all classified and cataloged in TCDB. Having a standardized classification system means that when a regulatory agency says “test for OATP1B1 inhibition,” everyone is talking about the same protein, the same family, and the same functional category.

Bacterial Efflux Pumps and Antibiotic Resistance

The drug-pump problem is not limited to human cancer cells. Bacteria use their own efflux pumps to expel antibiotics, and these pumps are a central driver of multidrug resistance in infectious disease. A single bacterial efflux pump can expel a wide range of structurally diverse antibiotics, which is why resistance to one antibiotic sometimes comes packaged with resistance to several others.²² TCDB classifies these bacterial transporters alongside their human counterparts, which gives researchers a comparative view. If a bacterial efflux pump belongs to the same superfamily as a human transporter, any drug designed to block it will need to be evaluated for off-target effects on the human version. If it belongs to a family with no human members, the selectivity problem is easier.

This comparative framework also helps in the study of environmental toxicology. Several transporters identified in TCDB are responsible for moving heavy metals like manganese into the central nervous system. Proteins including DMT-1, SLC30A10, transferrin, and ferroportin have all been identified as manganese carriers, and their overactivity or misregulation contributes to manganese-induced neurotoxicity.²³ Understanding which transporter families handle which metals, and where those families sit in TCDB’s phylogenetic tree, helps toxicologists predict which tissues are most vulnerable to metal accumulation.

De-orphaning Unknown Transporters

A large fraction of human transporter genes have no confirmed substrate or function. These “orphan” transporters are classified in TCDB by sequence and family membership, but their biological roles remain blank. De-orphaning them, which means figuring out what they transport and what happens when they fail, is an active area of research with direct medical implications. Every orphan that gets characterized is a potential new drug target or a new explanation for unexplained disease.

One striking recent example is SLC22A15. Using phylogenetic analysis guided by TCDB classifications, combined with metabolomic screening, researchers identified eight zwitterionic substrates of SLC22A15, including ergothioneine, carnitine, carnosine, and the drug gabapentin, plus four cationic substrates like thiamine and cimetidine.²⁴ The finding that a transporter handles gabapentin, a widely prescribed medication, immediately raises pharmacological questions about individual variation in drug response.

An even more unusual case is SLC22A10. This gene was an orphan transporter that turned out to be nonfunctional in modern humans due to a single amino acid change, proline at position 220, that prevents the protein from reaching the cell surface. In great apes, the same gene carries leucine at that position and functions as a transporter of steroid conjugates like estradiol-17β-glucuronide. When researchers swapped the proline back to leucine in the human protein, membrane localization and transport function were restored. Remarkably, both Neanderthal and Denisovan genomes also carry the proline variant, suggesting this transporter was lost during hominin evolution, not just in our species.²⁵ From a medical standpoint, this means SLC22A10 is essentially a pseudogene in humans. But it also illustrates how TCDB’s cross-species comparative data can reveal the evolutionary history of transporter function and flag cases where a human gene that “looks like” a transporter no longer is one.

Machine Learning and Computational Screening

Testing every new drug candidate against every relevant transporter in the lab is expensive and slow. Machine learning models trained on transporter interaction data offer a way to triage compounds computationally before running wet-lab experiments. Several research groups have built predictive models for ABC transporter substrates and inhibitors, achieving classification accuracy rates above 75% for substrate prediction and around 84% for inhibition prediction.²⁶ Similar approaches targeting a specific uptake transporter, OATP1B1 (important because it controls liver uptake of many statin drugs), identified new inhibitors with about 84% accuracy when predictions were tested in the lab.²⁷

A web-based tool called MegaTrans now bundles machine learning models for all the transporters specified in FDA drug interaction guidance, including OAT1, OAT3, OCT2, OATP1B1, OATP1B3, P-glycoprotein, BCRP, MATE1, and MATE2-K. Users can input a molecule’s structure and receive predictions about which of these transporters it might inhibit, with aggregate accuracy around 76% in second-round validation.²⁸ These kinds of tools reduce the need for brute-force screening and could eventually be plugged into generative AI systems that design drug candidates with transporter interactions already accounted for. The data underlying many of these models traces back to TCDB’s classification and substrate annotations, which provide the curated training sets that machine learning depends on.

Structural Biology Pushing the Field Forward

One reason transporters were historically hard to study is that they are membrane proteins, and membrane proteins resist the crystallization techniques that dominated structural biology for decades. Cryo-electron microscopy (cryo-EM) has changed that dramatically, allowing researchers to capture transporter structures at near-atomic resolution without crystals. The technique has been particularly transformative for ABC transporters, revealing how these pumps change shape during their transport cycle and how drug molecules get caught in or expelled from their binding pockets.²⁹ TCDB catalogs which transporters have had their three-dimensional structures solved, with data on over 1,500 deposited structures as of 2021.¹ Those structures feed directly into drug design: knowing the exact shape of a transporter’s binding site makes it possible to design molecules that fit precisely, rather than relying on trial and error.

Organellar Transporters and Emerging Pathology

Most attention has focused on transporters sitting in the outer membrane of cells, but transporters embedded in the membranes of organelles like mitochondria and lysosomes are turning out to be medically significant as well. ABCB10, for example, is an ABC transporter located in the inner mitochondrial membrane that plays roles in hemoglobin synthesis, antioxidant defense, and stabilization of iron import. When this transporter was knocked out specifically in heart muscle cells in animal models, the result was progressive cardiac fibrosis, increased cardiovascular risk markers, and mitochondrial structural damage. Further investigation in human cell lines showed that loss of ABCB10 led to iron and lipid peroxide accumulation in lysosomes, triggering a form of cell death called ferroptosis.³⁰ This kind of finding, linking a mitochondrial transporter defect to heart failure through iron-driven cell death, would be almost impossible to predict without a classification system that places ABCB10 in context alongside its ABC family relatives and their known disease associations.

The Gut Microbiome Connection

An area that has emerged more recently is the influence of gut bacteria on intestinal drug transporters. The composition and metabolic output of your gut microbiome can alter the expression and activity of key transporters in the intestinal lining, including P-glycoprotein, BCRP, and several organic anion-transporting polypeptides. Bacterial metabolites such as short-chain fatty acids, secondary bile acids, and tryptophan-derived indoles appear to be the molecular mediators of this regulation.³¹ The practical consequence is that two people taking the same oral drug can absorb it very differently depending on their microbial profiles. This variability is difficult to predict clinically, but as researchers map which bacterial species affect which transporters, TCDB’s classification of those transporters provides the shared language needed to make sense of the data. It is still early days for turning these findings into dosing guidance, but the gut-transporter axis helps explain a chunk of the frustrating unpredictability in how patients respond to oral medications.

1
PubMed Central. The Transporter Classification Database (TCDB): 2021 update
2
PubMed Central. TCDB: the Transporter Classification Database for membrane transport protein analyses and information
3
PubMed Central. TransAAP: an automated annotation pipeline for membrane transporter prediction in bacterial genomes
4
PubMed Central. Membrane transporters in drug development
5
PubMed Central. Epithelial plasma membrane transporters as drug targets
6
PubMed. Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease
7
PubMed Central. The genetic landscape of the human solute carrier (SLC) transporter superfamily
8
PubMed. Overview: ABC transporters and human disease
9
Journal of Biological Chemistry. Molecular Bases of Disease Retinoid Binding Properties of Nucleotide Binding Domain 1 of the Stargardt Disease-associated ATP Binding Cassette (ABC) Transporter, ABCA4
10
PubMed Central. Role of ABC transporters in cancer chemotherapy
11
PubMed. Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer
12
Drug Resistance Updates. Beyond the boundary: The emerging roles of ATP-binding cassette transporters in multidrug resistance (MDR) and therapeutic targeting in cancer
13
PubMed Central. Overview of Monoamine Transporters
14
PubMed Central. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy
15
PubMed. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
16
PubMed Central. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
17
PubMed. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
18
PubMed Central. Drug Delivery Across the Blood-Brain Barrier: A New Strategy for the Treatment of Neurological Diseases
19
PubMed Central. Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics
20
PubMed. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs)
21
PubMed. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier
22
PubMed Central. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors
23
PubMed Central. Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies
24
PubMed Central. Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies
25
Nature Communications. Illuminating the function of the orphan transporter, SLC22A10, in humans and other primates
26
Molecular Pharmaceutics. Machine Learning Modeling for ABC Transporter Efflux and Inhibition: Data Curation, Model Development, and New Compound Interaction Predictions
27
PubMed Central. Machine Learning Models Identify New Inhibitors for Human OATP1B1
28
PubMed Central. MegaTrans-machine learning models for drug transporters corresponding to the FDA guidance
29
PubMed. Cryo-EM of ABC transporters: an ice-cold solution to everything?
30
Bioscience Reports. Cardiomyocyte-specific deletion of the mitochondrial transporter Abcb10 causes cardiac dysfunction via lysosomal-mediated ferroptosis
31
PubMed Central. Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications